Latest Breaking News On - Chief executive officer emma walmsley - Page 4 : comparemela.com
How to Repel Elliott? Undo a $40 Billion Discount
May 12 2021, 4:12 AM
May 11 2021, 1:40 PM
May 12 2021, 4:12 AM
(Bloomberg Opinion) Doing a big demerger is an expensive and time-consuming exercise that underperforming companies often pursue in the hope of deterring a shareholder activist. This hasnât prevented GlaxoSmithKline Plc from attracting the attention of activist-in-chief Elliott Management Corp. That begs the question of what more the U.K. drugmaker should be doing.
(Bloomberg Opinion) Doing a big demerger is an expensive and time-consuming exercise that underperforming companies often pursue in the hope of deterring a shareholder activist. This hasnât prevented GlaxoSmithKline Plc from attracting the attention of activist-in-chief Elliott Management Corp. That begs the question of what more the U.K. drugmaker should be doing.
California
United-states
Pennsylvania
Cambridge
Cambridgeshire
United-kingdom
Stevenage
Hertfordshire
Emma-walmsley
Chris-hughes
Jonathan-symonds
Pascal-soriot
Astra, Glaxo Join Rush Back to Lab to Target Covid Variants
Bloomberg 2/3/2021 Suzi Ring, Tim Loh and Naomi Kresge © Photographer: DeFodi Images/Getty Images Europe TUEBINGEN, GERMANY - NOVEMBER 21: (BILD ZEITUNG OUT) the Logo of Curevac is seen on a sign in front of the CUREVAC building on November 21, 2020 in Tuebingen, Germany. (Photo by Harry Langer/DeFodi Images via Getty Images)
(Bloomberg) AstraZeneca Plc and GlaxoSmithKline Plc joined the rush to develop a new generation of vaccines against emerging variants of the coronavirus that could make the first shots less effective.
AstraZeneca and the University of Oxford are planning to have a shot available by the fall, in time for the next round of immunizations that may be required before winter. U.K. rival Glaxo and Germany’s CureVac NV teamed up to create next-generation messenger RNA vaccines to combat new strains.
Germany
South-africa
United-kingdom
British
German
Harry-langer-defodi
Andrew-pollard
Emma-walmsley
Oxford-covid
Bayer-ag
Glaxosmithkline-plc
University-of-oxford